Kamada (NASDAQ:KMDA) and Kedrion Biopharma announce a global collaboration
for the development, manufacturing and distribution of a human
plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin
(IgG) product as a potential treatment for coronavirus patients.
Pursuant to the agreed terms, Kedrion will provide
plasma from donors who have recovered from the virus and, upon receipt
of regulatory approvals, will be responsible for commercialization of
the product in the U.S., Europe, Australia, and South Korea.
Kamada is responsible for product development and
manufacturing and will assume distribution responsibility in all
territories outside those of Kedrion.
The initial primary focus will be to provide the
product in Italy, Israel and U.S. through various clinical programs,
while subsequently expanding development and commercialization efforts
to additional markets.
https://seekingalpha.com/news/3564576-kamada-up-15-premarket-on-covidminus-19-plan
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.